Iricryn

Bimatoprost, the active ingredient in Iricryn, is a prostaglandin analog presented as an ophthalmic solution for ocular use. It works by increasing uveoscleral outflow of aqueous humor, thereby reducing intra‑ocular pressure. The medication is indicated for the management of open‑angle glaucoma and ocular hypertension in adult patients.

GNH USA supplies Iricryn as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory conformity across markets. Our distribution network adheres to EU standards and provides reliable logistics for timely delivery.

Iricryn (bimatoprost) is a prostaglandin analog used to lower intra‑ocular pressure in glaucoma‑related conditions.

- Open‑angle glaucoma: reduces intra‑ocular pressure to slow visual field loss. - Ocular hypertension: lowers pressure to prevent progression to glaucoma. - Secondary open‑angle glaucoma: helps control pressure when other agents are insufficient.

Iricryn may cause ocular and peri‑ocular reactions.

Common Side Effects: - Eye redness: mild conjunctival hyperemia. - Itching or irritation: transient discomfort. - Foreign body sensation: feeling of grit in the eye. - Increased eyelash growth: longer, thicker lashes. - Darkening of iris: gradual pigmentation change. - Blurred vision: temporary focusing difficulty.

Serious or Rare Side Effects: - Severe eye inflammation: uveitis or iritis. - Allergic reaction: swelling, rash, or severe itching. - Vision loss: sudden decrease in visual acuity. - Ocular infection: bacterial or fungal keratitis. - Persistent ocular pain: unrelieved discomfort. - Corneal edema: swelling of the cornea.

Before using Iricryn, consider the following safety measures.

- Pregnancy: safety not established; avoid unless benefit outweighs risk. - Breastfeeding: unknown safety; use with caution. - Active ocular infection: contraindicated until infection resolves. - Intra‑ocular pressure monitoring: check pressure after initiation and periodically. - Concurrent prostaglandin analogs: avoid combined use to prevent excessive pressure reduction. - Contact lens wearers: remove lenses before instillation; may cause discoloration. - Store at room temperature: keep in original container, protect from light and moisture.

Iricryn can interact with other ophthalmic agents.

Major Interactions (Avoid): - Other intra‑ocular pressure‑lowering drops: risk of excessive pressure drop. - Ocular anesthetics: may increase corneal toxicity. - Systemic carbonic anhydrase inhibitors: potential additive IOP‑lowering effect.

Moderate Interactions (Monitor Closely): - Beta‑blocker eye drops: additive IOP reduction; monitor pressure. - Topical steroids: may diminish bimatoprost efficacy. - Non‑steroidal anti‑inflammatory eye drops: increased risk of ocular irritation.